The 2022 guidelines also provide a Class IIa, Level of evidence B recommendation for BNP or NT-proBNP-based screening for patients at risk of developing heart failure followed by team-based care, including a cardiovascular specialist optimizing goal-directed medical therapy (GDMT), as a strategy to prevent the development of new-onset HF and left ventricular dysfunction. This evidence concerns the gene NPPB and hydrops fetalis.